[The pharmacologic properties and therapeutic effectiveness of the new antidepressant preparation Azaphen].
D000328:Adult; D000368:Aged; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001714:Bipolar Disorder / Q000188:drug therapy; D002415:Cats; D003863:Depression / Q000188:drug therapy*; D003865:Major Depressive Disorder / Q000188:drug therapy; D004285:Dogs; D004357:Drug Synergism; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D012559:Schizophrenia / Q000188:drug therapy; D013747:Tetrabenazine / Q000037:antagonists & inhibitors
D000928:Antidepressive Agents; D012110:Reserpine; D000661:Amphetamine; D013747:Tetrabenazine
Farmakologicheskie svoĭstva i lechebnaia éffektivnost' novogo antidepressivnogo preparata azafena.